Background
Cristina Adriana Popa
The Protein Pendulum in CKD: supplement or ...

This week, we will discuss an old dilemma in nephrology. To restrict or supplement the proteins? Premise: advanced CKD and dialysis.

The Protein Pendulum in CKD: supplement or restrict?
Background, summary
Brian Rifkin
Chimerism and Immune Tolerance: Can We Says ...

This week, we will discuss the use of creating chimeras to induce immune tolerance and its potential to decrease or eliminate the need for immunosuppression in kidney transplant recipients.

Chimerism and Immune Tolerance: Can We Says Goodbye to Immunosuppression?
Meta
joel topf
NephJC 2025 Fall Pledge Drive

Help keep NephJC a vital, original, and unbiased source of medical education.

NephJC 2025 Fall Pledge Drive
Background, summary
Brian Rifkin
PREVENT, Detect, Treat: What’s New in the 2025 ...

This week, we will discuss the AHA/ACC 2025 hypertension guideline update. Wow, have eight years flown by?

PREVENT, Detect, Treat: What’s New in the 2025 Hypertension Toolkit
Background
swapnil hiremath
In ESRD is spironolactone an overACHIEVEr?

This week, we will discuss the ACHIEVE trial. Will spironolactone achieve CV benefits in ESRD?

In ESRD is spironolactone an overACHIEVEr?

Background

IgA Nephropathy: Testing Steroids Again

IgA Nephropathy: Testing Steroids Again

Stop-IgAN suggested steroids may not be useful in patients with intermediate range proteinuria. Now, in a different population with more proteinuria, TESTING finds a mixed result: some benfit + more adverse events. Should we keep on TESTING? 

Encapsulating Peritoneal Sclerosis: The ISPD Advice

Encapsulating Peritoneal Sclerosis: The ISPD Advice

This week, we will discuss the fresh-off-the-press ISPD guidelines on encapsulating peritoneal sclerosis. We are happy to have support from the ISPD for organizing this - and making the manuscript open, and also the ISPD Vancouver 2018 team, who will be co-hosting the #NephJC chat. 

Can Canaglifozin Communicate Consistency with CANVAS?

Can Canaglifozin Communicate Consistency with CANVAS?

Were the EMPA-REG Renal results chance, or is this a class effect? Let's take a deep dive into CANVAS, published in the NEJM recently, which examined the cardiovascular safety of canaglifozin in type 2 diabetes.